Procavea Biotech AG

Procavea Biotech AG is an ETH Zurich spin-off advancing a first-in-class siRNA delivery platform. While standard systems are restricted to liver delivery, Procavea’s proprietary OP protein cage enables extrahepatic delivery, specifically targeting the adrenal cortex - a region previously unreachable by RNAi. The lead program, PCV-001, targets Primary Aldosteronism, converting a validated pathway into a durable, quarterly-dosed therapy. Procavea employs a hybrid business model: developing an internal adrenal pipeline while partnering with pharma to enable delivery to tissues like the CNS and kidney.